Cerus Corporation (CERS) Submits Investigational Device Exemption (IDE) Supplement to FDA for Phase III INTERCEPT Red Blood Cell Study  
3/21/2012 6:50:48 AM

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has submitted an IDE supplement to the U.S. Food and Drug Administration (FDA) for the company’s proposed Phase III trial of the INTERCEPT Blood System for red cells in patients receiving chronic red cell transfusion support for sickle cell disease (SCD) or thalassemia.